2018
DOI: 10.1111/hae.13600
|View full text |Cite
|
Sign up to set email alerts
|

Pain assessment and management in haemophilia: A survey among Italian patients and specialist physicians

Abstract: Pain is under-recognized and unsatisfactorily addressed by haemophilia treatment centre (HTC) clinicians, with discrepant management compared to PWH responses. Education in systematic pain assessment and multidisciplinary treatment and development of management guidelines are highly needed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
31
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 28 publications
(35 citation statements)
references
References 35 publications
1
31
0
Order By: Relevance
“…Healthcare professionals are known to have poor recognition and understanding of pain management in children with haemophilia . A recent publication by Tagliaferri et al concurs that pain is under‐recognized and unsatisfactorily addressed, with discrepant clinician and patient views. Moreover, a study by Lambing et al revealed that there is poor agreement between patients and caregivers concerning pain perception, especially for chronic pain.…”
Section: Discussionmentioning
confidence: 99%
“…Healthcare professionals are known to have poor recognition and understanding of pain management in children with haemophilia . A recent publication by Tagliaferri et al concurs that pain is under‐recognized and unsatisfactorily addressed, with discrepant clinician and patient views. Moreover, a study by Lambing et al revealed that there is poor agreement between patients and caregivers concerning pain perception, especially for chronic pain.…”
Section: Discussionmentioning
confidence: 99%
“…We relied on physician reporting of pain. There is evidence that physician-and patient-reported assessments and treatment of haemophilia-related pain may not correlate well, and physicians tend to underestimate pain compared with patients [24][25][26] . In this study, physicians reported that almost two thirds of patients had pain, which was moderate in 21% and severe in 2%; there were seven patients with severe pain.…”
Section: Discussionmentioning
confidence: 99%
“…A further option is represented by anti-inflammatory therapy using cyclooxygenase 2 (COX-2) inhibitors, monoclonal antibodies anti-TNFα and anti-IL-1β with the aim to avoid the self-maintaining inflammatory cycle. Evidence showed that COX-2 inhibitors (celecoxib and rofecoxib) are safe and effective in treating chronic synovitis and joint pain, and currently represent a potential choice to treat pain in hemophilia patients (Rattray et al, 2006;Tagliaferri et al, 2018;Santoro et al, 2020). In 2013, Melchiorre et al reported data about a drastic reduction of joint bleeding in three patients treated with an anti-TNFα monoclonal antibody.…”
Section: Challenges In the Treatment Of Ha (Figure 2)mentioning
confidence: 99%